BioSpace News Archive

AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin complex ABP-450 injection for therapeutic indications, announced the appointment of Alex Wilson to the role of General Counsel.

Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced that the European Medicines Agency Committee for Orphan Medicinal Products issued a positive opinion on the company’s application for orphan drug designation for AK-OTOF, a gene therapy intended for the treatment of otoferlin gene-mediated hearing loss.

Algernon Pharmaceuticals Inc. is pleased to announce that it has initiated an NP-120 (“Ifenprodil”) small cell lung cancer (“SCLC”) research program and has appointed Dr. William North, professor emeritus at Dartmouth College and cancer research pioneer, as lead consultant.

scPharmaceuticals Inc. today announced financial results for the second quarter ended June 30, 2021 and provided a business update.

BD, a leading global medical technology company, announced the launch of a new benchtop cell analyzer that brings sophisticated flow cytometry capabilities to laboratories of all sizes.

Immunocore Holdings plc, a late-stage biotechnology company pioneering the development of a novel class of T cell receptor bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, announced its financial results for the quarter and six months ended June 30, 2021 and provides a portfolio update.

Perrigo Company plc, a leading global provider of Consumer Self-Care Products, announced financial results from continuing operations for the second quarter of fiscal year 2021 ended July 3, 2021.

Clene Inc. along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, announced the completion of two lease agreements that will more than quadruple the company’s manufacturing capacity for its lead asset, CNM-Au8®, a gold nanocrystal suspension.

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that the Company has launched a new website: https://ponstreatment.com, created to serve as a resource for U.S.-based patients and physicians.

Photocure ASA reported Hexvix®/Cysview® revenues of NOK 88.9 million in the second quarter of 2021, and EBITDA of NOK 5.8 million, driven by growth in the U.S. segment and the continued successful launch in European markets reacquired in 2020.